STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
KRAS is the most common oncogenic driver in lung adenocarcinoma (LUAC). We previously reported that STK11/LKB1 (KL) or TP53 (KP) comutations define distinct subgroups of KRAS-mutant LUAC. Here, we examine the efficacy of PD-1 inhibitors in these subgroups. Objective response rates to PD-1 blockade differed significantly among KL (7.4%), KP (35.7%), and K-only (28.6%) subgroups (P < 0.001) in the Stand Up To Cancer (SU2C) cohort (174 patients) with KRAS-mutant LUAC and in patients treated with nivolumab in the CheckMate-057 phase III trial (0% vs. 57.1% vs. 18.2%; P = 0.047). In the SU2C cohort, KL LUAC exhibited shorter progression-free (P < 0.001) and overall (P = 0.0015) survival compared with KRASMUT;STK11/LKB1WT LUAC. Among 924 LUACs, STK11/LKB1 alterations were the only marker significantly associated with PD-L1 negativity in TMBIntermediate/High LUAC. The impact of STK11/LKB1 alterations on clinical outcomes with PD-1/PD-L1 inhibitors extended to PD-L1–positive non–small cell lung cancer. In Kras-mutant murine LUAC models, Stk11/Lkb1 loss promoted PD-1/PD-L1 inhibitor resistance, suggesting a causal role. Our results identify STK11/LKB1 alterations as a major driver of primary resistance to PD-1 blockade in KRAS-mutant LUAC. Significance: This work identifies STK11/LKB1 alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma. Genomic profiling may enhance the predictive utility of PD-L1 expression and tumor mutation burden and facilitate establishment of personalized combination immunotherapy approaches for genomically defined LUAC subsets. Cancer Discov; 8(7); 822–35. ©2018 AACR. See related commentary by Etxeberria et al., p. 794. This article is highlighted in the In This Issue feature, p. 781
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In NSCLC, alterations in STK11, KEAP1, and TP53 define biologically distinct molecular subsets with different immune phenotypes and treatment outcomes [75,76].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [9]
In the citing paper
“However, co-mutations of other genes, especially STK11/LKB1 and KEAP1, were found to mediate resistance to anti-PD-1/PD-L1 therapy in KRAS-mutant NSCLC [156].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [156]
In the citing paper
“KRAS-mutant tumors with TP53 co-mutation often show higher inflammatory signaling and may be more responsive to immune checkpoint blockade.”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [76]
23 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
Self-citationNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 3×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“38(0) 38(0) 28(3) 17(8) 2(20) 1(21) 1(21) 1(21) 0(22) 0(22) 61(0) 29(5) 12(14) 5(19) 3(20) 2(21) 2(21) 1(22) 0(23) 18(2) 9(3) 5(5) 3(7) 1(8) 1(8) 0(8) 0(8) 61(0) 14(3) 7(4) 5(4) 3(5) 2(5) 1(5) 0(5) 0(5) 3 6 9 12”
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Months KL KP K-only 54(0) 56(0) 64(0) 11(2) 26(3) 29(0) 5(3) 14(6) 20(3) 4(3) 9(10) 9(8) 2(4) 5(14) 3(13) 2(4) 1(15) 2(14) 1(4) 0(15) 2(14) 1(4) 0(15) 1(14) 0(4) 0(15) 0(15)”
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 4×
“KL KP K-only 54(0) 56(0) 64(0) 25(5) 36(2) 45(4) 10(12) 19(14) 27(18) 4(16) 4(26) 4(34) 2(17) 1(29) 1(37) 1(18) 1(29) 1(37) 1(18) 1(29) 1(37) 0(19) 1(29) 0(38) 0(19) 0(30) 0(38) KL KRASSTK11”
InfluentialPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“11(0) 2(1) 0(3) 0(3) 0(3) 0(3) 0(3) 11(0)”
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Cited by
Items 901–1,000 of 1,004
Zhou, L. Q., Huang, L., Xu, Q., Lv, Y., Wang, Z., Zhan, P., Han, H., Shao, Y. W., Lin, D., Lv, T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.596542 · Cited by 12
“An increasing number of studies have suggested other potential biomarkers, including somatic mutations in specific genes (11, 12), copy number alterations affecting immune-related genes (13), tumor infiltrating lymphocytes (14), and inflamed gene expression profiles (15, 16).”
BackgroundWu, J., Zhou, J., Xu, Q., Foley, R., Guo, J., Zhang, X., Tian, C., Mu, M., Xing, Y., Liu, Y., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.751800 · Cited by 9
Xia, L., Yu, Y., Lan, F., Yan, J., Li, J., Li, W., & Xia, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.760703 · Cited by 11
“Not only the data from Checkmate057 (4) and Atlantic trial (5) in advancedNSCLC, but also the results derived from IMpower010 (6) in an adjuvant setting, PACIFIC trial (7) in a locally advanced setting, and IMMUNOTARGET registry (8) from the real-world evidence showed blunted clinical activity of ICI in lung cancer ha…”
ResultJain, K. K. (2020) · Springer eBooks · doi:10.1007/978-3-030-62080-6_20 · Cited by 13
Emerging genetic biomarkers in lung adenocarcinoma
Barbar, J., Armach, M., Hodroj, M. H., Assi, S., Nakib, C. E., Chamseddine, N., & Assi, H. I. (2022) · SAGE Open Medicine · doi:10.1177/20503121221132352 · Cited by 10
Bironzo, P., Passiglia, F., & Novello, S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.08.91 · Cited by 9
“91 Prognostic Index score (9) as well as (STK11/LKB1 genes mutations or other rare oncogenic alterations) (10,11) could further dissect this apparently homogenous group.”
BackgroundHeterogeneity in MET-Aberrant NSCLC
Le, X. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.01.1609 · Cited by 10
Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0998 · Cited by 9
“Tumors with loss-of-function mutations in STK11 respond poorly to immune checkpoint blockade, leading to shorter progression-free survival and overall survival in these patients (1, 5, 6).”
InfluentialSelf-citationMechanism of resistance to immune checkpoint inhibitors
Pandey, M. R., & Ernstoff, M. S. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2018.015 · Cited by 11
“Other important pathways for resistance include STK11/LKB1 mutation in KRAS mutant lung adenocarcinoma that has been shown to directly induce resistance to ICI therapy, with a significant decrease in the response rate and overall survival([44]).”
BackgroundCombination strategies of immunotherapy in non-small cell lung cancer: facts and challenges
Li, C., & Song, Y. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001610 · Cited by 11
Stinchcombe, T. E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-530 · Cited by 11
“The mechanisms is due to silencing of the stimulator of interferon genes (STING) expression (39,40).”
Chen, Y., Chen, X., Li, Z., Zhu, Y., Liu, F., & Cai, J. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10401-0 · Cited by 10
“Skoulidis et al. found that STK11 deficiency promoted PD-1/PD-L1 inhibitor resistance through gene profiling analysis in KRAS mutant lung adenocarcinoma mouse model (Skoulidis et al. 2018).”
BackgroundKRAS G12C mutation: from undruggable target to potentially agnostic biomarker
Osta, B. E. E. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-174 · Cited by 10
“Peters S, Cho BC, Luft A, et al. Association between KRAS/STK11/KEAP1 mutations and outcomes in POSEIDON: Durvalumab ± tremelimumab + chemotherapy in mNSCLC. World Conference on Lung Cancer Abstract OA1504; Vienna, Austria.”
BackgroundInfluentialJin, G., Ma, M., Yang, C., Zhen, L., & Feng, M. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15034 · Cited by 9
“4% of subjects obtained a complete or partial response to the treatment, which indicates that a therapy targeting PD-1/PD-L1 axis is imminently required to improve response rates.(18) Of interest, some studies have repeatedly proven the key anticancer mechanism of TCM lies in regulating immune cells and mediating tumo…”
BackgroundAn Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development
Wang, Q., Xie, B., Sun, J., Li, Z., Xiao, D., Tao, Y., & She, X. (2024) · Journal of Cancer · doi:10.7150/jca.92101 · Cited by 11
“The relationship between TMB and several factors, such as the response to immune checkpoint blockade, specific driver mutations, and the extent of immune infiltration, has been shown in previous studies[18-21].”
BackgroundResultGiraud, J.-S., Jouinot, A., Pasmant, É., & Tlemsani, C. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00524-x · Cited by 9
“Wecompared the NF1 -mutated lung adenocarcinomas pro fi le with TP53-and KRAS -mutated tumors which are likely associated with ICI response 10,16,18 , and KEAP1-and STK11 -mutated tumors which are likely known to be resistant to ICI 18 – 21 .”
BackgroundNEDD1 overexpression increases cell proliferation, tumor immune escape, and drug resistance in LUAD
Zhuo, T., Wu, Z., Chen, S., Yang, C., Huang, H., Gan, J., Lyu, J., Xiao, J., Li, Z., Qin, S., et al. (2024) · Journal of Cancer · doi:10.7150/jca.91671 · Cited by 9
“[42-44] In contrast, the efficacy of CAR-T cell therapy in lung cancer has been limited due to the absence of distinct surface antigens.”
BackgroundCRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells
Abounar, S. A., El-Nikhely, N. A., Turkowski, K., Savai, R., & Saeed, H. M. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25169086 · Cited by 13
“…therapy despite the unpredictable Lym-phocytes cultured with A549 cells with low PD-L1 expression secreted a different set of cytokines that tended to reduce cancer cell cytotoxicity even in the absence of T lymphocytes. possibility of resistance in almost half of lung cancer patients [19].”
BackgroundInfluentialPrediction of immunotherapy response using mutations to cancer protein assemblies
Kong, J., Zhao, X., Singhal, A., Park, S., Bachelder, R. E., Shen, J., Zhang, H., Moon, J., Ahn, C.-H., Ock, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.ado9746 · Cited by 10
Zhou, N., Leung, C. H., William, W. N., Weissferdt, A., Pataer, A., Godoy, M. C. B., Carter, B. W., Fossella, F. V., Tsao, A. S., Blumenschein, G. R., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009677 · Cited by 10
Self-citationNext-generation immunotherapy: igniting new hope for lung cancer
Li, M. S. C., Chan, A. L. S., Mok, K. K. S., Chan, L. L., & Mok, T. S. K. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241302021 · Cited by 9
Cooper, W. A., Amanuel, B., Cooper, C. L., Fox, S. B., Graftdyk, J. W. A., Jessup, P. J., Klebe, S., Lam, W., Leong, T. Y.-M., Lwin, Z., et al. (2025) · Pathology · doi:10.1016/j.pathol.2025.02.001 · Cited by 9
Immune checkpoint inhibitors: From friend to foe
Rajak, P. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102033 · Cited by 10
“WNT/ β -catenin, PTEN, LKB1, and EGFR pathways are associated with disruption in the production of these chemokines and hence contribute to the ICI resistance [120 – 122].”
Optimizing early-phase immunotherapy trials: the role of biomarker enrichment strategies
Catani, G., Morchón-Araujo, D., Mirallas, O., Sánchez-Pérez, V., Nuciforo, P. G., Villacampa, G. J., Dienstmann, R., Vivancos, A. P., Garralda, E., & Hernando‐Calvo, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664443 · Cited by 14
Regulatory T Cell Metabolism in Cancer
Mortezaee, K. (2025) · Immunology · doi:10.1111/imm.70096 · Cited by 192
Wang, Y., Xiang, Y., Chen, X.-W., Zhang, T., Wang, J.-Y., Liu, W.-Y., Deng, L., Wang, L.-H., Gao, S., & Bi, N. (2026) · Military Medical Research · doi:10.1186/s40779-025-00679-z · Cited by 14
“Although previous studies have shown that tumor tissue-based STK11 , KEAP1 , and CDKN2A/B mutations are adverse prognostic factors [51, 52], we further confirm that ctDNA-based STK11 , KEAP1 , and CDKN2A can predict unfavorable outcomes in patients with non-metastatic NSCLC. Prior research has…”
Self-citationTumor heterogeneity: development, mechanisms, and therapeutic implications
Zhang, J., Li, H., Ru, S., Feng, H., Guo, J., Sun, D., Xiang, T., Xu, D., & Luo, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02749-7 · Cited by 21
Self-citationInflamed T cells and stroma drive gut tumors
Hollstein, P. E., & Shaw, R. J. (2018) · Science · doi:10.1126/science.aau4804 · Cited by 11
Harnessing Synthetic Lethal Interactions for Personalized Medicine
Shieh, G. S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010098 · Cited by 9
“For example, LKB1 was reported to be a putative tumor-intrinsic immune evasion gene [46].”
BackgroundRojas, L., Mayorga, D., Ruíz-Patiño, A., Rodríguez, J. K., Cardona, A. F., Archila, P., Avila, J. T., Bravo, M., Ricaurte, L., Sotelo, C., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100500 · Cited by 10
“STK11inactivating mutations are associated with an inadequate response to ICI, mainly when associated with other mutations such as KRAS, shortening survival.(32) HPV has also been associated with decreased STK11 mRNA levels,(15) suggesting that HPV-infected tumors might have a poorer prognosis and response to ICI, but…”
BackgroundFancelli, S., Caliman, E., Mazzoni, F., Paglialunga, L., Michelet, M. R. G., Lavacchi, D., Berardi, R., Mentrasti, G., Metro, G., Birocchi, I., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.968064 · Cited by 11
“, nivolumab, pembrolizumab, atezolizumab, and ipilimumab) induce T-cell reactivation in several neoplasms, although their e fficacy is patchy due to exis t ing mechanisms of immunosuppression (16, 17).”
BackgroundHozumi, H., & Shimizu, H. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad133 · Cited by 11
Shaverdashvili, K., Reyes, V. E., Wang, H., Mehta, D. R., Marsh, C., Waas, J. K., VanderWeele, R. A., Peracha, S. M., Liang, H., Socinski, M. A., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102317 · Cited by 10
“25 Knowledge of STK11 mutations and other genomic alterations in our trial population might further de fi ne patients more or less likely to derive bene fi t in the PS 2 setting.”
BackgroundHuang, X., Feng, Y., Li, Y., Ding, H., Huang, X., Chen, C., Yu, Z., Zhang, J., Xu, X., Ma, D., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111286 · Cited by 10
Self-citationOudart, J., Garinet, S., Leger, C., Barlési, F., Mazières, J., Jeannin, G., Audigier-Valette, C., Moro‐Sibilot, D., Langlais, A., Amour, E., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107508 · Cited by 12
Long duration of immunotherapy in a STK11 mutated/KRAS wild-type non-small cell lung cancer patient
Domingues, I., Cedrés, S., Callejo, A., Vivancos, A. P., Martínez‐Martí, A., & Felip, E. (2020) · Pulmonology · doi:10.1016/j.pulmoe.2019.05.002 · Cited by 9
“The reported STK11 pS69* mutation results in a premature stop codon within its kinase domain, associated to more aggressive tumours, shorter progression-free survival and overall survival.(1,3) Additionally, this mutation has been associated with significantly shorter time on PD1/PD-L1 blockade therapy in NSCLC (or ev…”
BackgroundMulshine, J. L., Ujházy, P., Antman, M., Burgess, C. M., Kuzmin, I., Bunn, P. A., Johnson, B. E., Roth, J. A., Pass, H. I., Ross, S. M., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29564 · Cited by 10
“More recently, the lung cancer cell lines were used in exploring the relationship of oncogenotypes (like TSK11/ LKB1 mutations to resistance to checkpoint inhibitors) to new immunotherapies for lung cancer.(50,51) The University of Texas (UTSW/MDACC) Lung Cancer SPORE (P50CA070907), through use of these lung cancer pr…”
BackgroundSelf-citationLantuéjoul, S., Damiola, F., & Adam, J. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.03.23 · Cited by 9
Biomarker Development for Metastatic Renal Cell Carcinoma: Omics, Antigens, T-cells, and Beyond
Miron, B., Xu, D., & Zibelman, M. R. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040225 · Cited by 10
“However, interpretation of this signature thus far is limited since annotation of treatments record and outcome are not available in the TCGA data and survival data was calculated prior to the approval of ICBs.”
BackgroundKRAS G12C inhibition and innate immune targeting
Tani, T., Kitajima, S., Conway, E. B., Knelson, E. H., & Barbie, D. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1902991 · Cited by 11
“free survival and overall survival were also significantly shorter in KL tumors, which demonstrated few PD-L1 positive tumor cells and CD8-positive T-cells [52].”
BackgroundBaglivo, S., Bianconi, F., Metro, G., Gili, A., Tofanetti, F. R., Bellezza, G., Ricciuti, B., Mandarano, M., Teti, V., Siggillino, A., et al. (2021) · Genes · doi:10.3390/genes12070992 · Cited by 9
“Anti-PD-1/PD-L1 therapy does not achieve a significant survival improvement in patients with EGFR mutations [11–13] or with co-occurring KRAS/STK11 alterations [14].”
BackgroundPattern of disease and response to pembrolizumab in recurrent cervical cancer
Miller, K., Filippova, O. T., Hayes, S. A., Abu‐Rustum, N. R., Aghajanian, C. A., Broach, V. A., Ellenson, L. H., Selenica, P., Jewell, E. L., Kyi, C., et al. (2021) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2021.100831 · Cited by 11
The efficacy of immune checkpoint inhibitors in thoracic malignancies
Remón, J., Facchinetti, F., & Besse, B. (2021) · European Respiratory Review · doi:10.1183/16000617.0387-2020 · Cited by 12
Kang, N., Tan, K. T., Li, C., & Kuo, Y. (2021) · Current Oncology · doi:10.3390/curroncol28060388 · Cited by 9
Present and Emerging Biomarkers in Immunotherapy for Metastatic Non-Small Cell Lung Cancer: A Review
Khwaja, R., & Chu, Q. S.-C. (2022) · Current Oncology · doi:10.3390/curroncol29020043 · Cited by 13
Farooq, H., Bien, H., Chang, V. T.-S., Becker, D. J., Park, Y.-H., & Bates, S. E. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.06.008 · Cited by 12
Huang, Y., Zhang, H., Feng, J., & Tang, B. (2022) · Apmis · doi:10.1111/apm.13271 · Cited by 11
“[16] found that the immune cell infiltration level of STK11 mutant LUAD patients was lower than that of STK11 wild-type LUAD patients, with significantly reduced infiltration of CD8+/CD4+ T cells, B cells, neutrophils, and dendritic cells, macrophages.”
BackgroundResultInfluentialLeal, J. L., & John, T. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.08.009 · Cited by 9
Adagrasib: a novel inhibitor for KRAS G12C -mutated non-small-cell lung cancer
Guo, M. Z., Marrone, K. A., Spira, A. I., & Rosner, S. (2023) · Future Oncology · doi:10.2217/fon-2022-1106 · Cited by 11
Immunotherapy in Non-Small-Cell Lung Cancer: from Targeted Molecules to Resistance Patterns
Brassart‐Pasco, S., Dalstein, V., Brassart, B., Dewolf, M., Clavel, C., & Oudart, J. (2020) · Pharmacogenomics · doi:10.2217/pgs-2020-0021 · Cited by 9
Zhang, Z., Wang, J., Mao, J., Li, F., Chen, W., & Wang, W. (2020) · BioMed Research International · doi:10.1155/2020/5171242 · Cited by 10
Self-citationPrognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer
Luo, X., Peng, S., Ding, S., Zeng, Q., Wang, R., Ma, Y., Chen, S., Wang, Y., & Wang, W. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01756-8 · Cited by 11
Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation
An, J., Yan, M., Yu, N., Chennamadhavuni, A., Furqan, M., Mott, S. L., Loeffler, B. T., Kruser, T. J., Sita, T. L., Feldman, L. E., et al. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-177 · Cited by 10
“Potential mechanisms for the STK11 resistance to ICI include impaired activity of effector T cells, epigenetic changes of tumor cells, modification of the cytokine and/or chemokine milieu, and diminished tumor antigenicity (11).”
BackgroundInfluentialSTK11 and KEAP1 Mutations in Lung Adenocarcinoma: Solving the Puzzle Continues
Dziadziuszko, R. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.004 · Cited by 10
“Its inactivation, frequent in lung adenocarcinomas, was found to be associated with reduced density of effector T lymphocytes, diminished response rate, and inferior progression-free survival of patients with co-occurring KRAS mutations, when treated with immune checkpoint inhibitors.(1) Tumors with loss of STK11 were…”
BackgroundImaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy
van Genugten, E. A. J., Weijers, J. A. M., Heskamp, S., Kneilling, M., van den Heuvel, M. M., Piet, B., Bussink, J., Hendriks, L. E. L., & Aarntzen, E. H. J. G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.786089 · Cited by 15
“For example, glucose consumption by cancer cells might be a metabolic adaptation to restrict T-cell effector function (26, 49).”
BackgroundUllah, A., Ahmed, A., Yasinzai, A. Q. K., Lee, K. T., Khan, I., Asif, B., Khan, I., Tareen, B., Kakar, K., Andam, G., et al. (2023) · Cancers · doi:10.3390/cancers15092469 · Cited by 9
“Furthermore, concurrent TP53/KRAS mutations may serve as indication that the PSC may respond well to immune checkpoint inhibition [22,44].”
BackgroundZhang, X., Zhang, Y., Gao, X., Zhang, Y., & Chen, Y. (2023) · Pharmaceuticals · doi:10.3390/ph16060871 · Cited by 10
“Immunotherapy has become a research hotspot in the treatment of LUAD in recent years [30].”
BackgroundLagoudaki, E. D., Koutsopoulos, A. V., Sfakianaki, M., Papadaki, C., Manikis, G. C., Voutsina, A., Trypaki, M., Tsakalaki, E., Fiolitaki, G., Hatzidaki, D., et al. (2024) · Cancers · doi:10.3390/cancers16101818 · Cited by 9
The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer
Lui, K., Cheung, K., Ng, W. W. M., Wang, Y., Au, D. W. H., & Cho, W. C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211954 · Cited by 11
“…(missense mutation point unspecified in this study) [143] TP53+TTN co-mutations [144] Resulting in negative ICI responses EGFR with low PD-L1 expression [148] K-Ras+KEAP1+STK11 co-mutations [94,151] STK11/LKB1+K-Ras co-mutations [147] TP53 (truncation) [69] TP53-R175H missense mutation [70]”
Novel and potent MICA/B antibody is therapeutically effective in KRAS LKB1 mutant lung cancer models
Kowash, R., Sabnani, M. K., Gray, L. T., Deng, Q., Saleh, N. U. A., Girard, L., Naito, Y., Masahiro, K., Minna, J. D., Gerber, D. E., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009867 · Cited by 11
“9 41 MICA/B are widely expressed across NSCLC and other cancer types, making our therapeutic strategy widely applicable.”
Rocha, P., Bach, R., Masfarré, L., Hernandez, S. D., Navarro-Gorro, N., Rossell, A., Villanueva, X., Giner, M., Sanchéz, I., Galindo-Campos, M. A., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2469377 · Cited by 9
Self-citationHuang, C., Qiu, Z., Huang, H., Xiao, X., Du, F., Ji, J., Xu, X., Jiang, X., Wang, Y., & Gao, C. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03011-7 · Cited by 11
“In the future, the identi fi cation of reliable predictive biomarkers for immunotherapy response is anticipated to facilitate more precise patient strati fi cation, thereby enhancing therapeutic ef fi cacy and improving clinical outcomes.”
Marković, F., Milin-Lazovic, J. S., Nikolić, N., Golubovic, A., Stjepanović, M., & Kontić, M. (2025) · Current Oncology · doi:10.3390/curroncol32060365 · Cited by 10
Khalil, M., & Tsao, M. (2025) · Cancers · doi:10.3390/cancers17132199 · Cited by 10
“Skoulidis et al. [34] assessed an MDACC cohort with 66 non-squamous NSCLC patients treated with PD-1/PD-L1 inhibitors with available genomic profiling and PD-L1 expression.”
KRAS-targeted therapies in cancer: novel approaches and overcoming resistance
Tang, D., Kroemer, G., & Kang, R. (2025) · BMJ Oncology · doi:10.1136/bmjonc-2025-000946 · Cited by 16
“For instance, STK11 mutations are associated with reduced T-cell infiltration and poor response to immune check-point blockade (ICB) in KRAS - mutant NSCLC, 27 whereas KEAP1 mutation or loss enhances NFE2-like BZIP transcription factor 2 (NFE2L2) activity, promoting resistance to oxidative damage and targeted therapie…”
Influentialvan der Geest, D., Vliet, A. V., Peeper, D. S., Haanen, J. B. A. G., Smit, E. F., & Theelen, W. S. M. E. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013110 · Cited by 9
“25 46 Whether LBK1 loss is directly responsible for resistance to ICI is debatable, since tumors with a high TMB show response to ICI regardless of the presence of LKB1 alteration.”
A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors
Bertucci, A., -, T. K., Billon, E., Fernez, T., & Rochigneux, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1735741 · Cited by 13
“Skoulidis et al., identi fi ed STK11/LKB1 inactivation as a major tumour-intrinsic driver of primary resistance to PD-1 blockade in KRAS-mutant NSCLC (71).”
Matschke, J., Larafa, S., & Jendrossek, V. (2021) · Biochemical Society Transactions · doi:10.1042/bst20200866 · Cited by 10
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
Brazel, D., Kim, J., & Ou, S. I. (2023) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s403614 · Cited by 8
“All three have been shown to negatively modulate response to immunotherapy.(21,22) Indeed, in the largest survey of KRAS mutations in solid and liquid tumors, STK11 and KEAP1 mutations were positively associated with KRAS G12C mutation non-squamous NSCLC.”
BackgroundSelf-citationXin, Z., You, L., Li, J., Na, F., Chen, M., Song, J., Bai, L., Chen, H., Zhai, J., Zhou, X., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110469 · Cited by 9
Olsen, A., Lebedeva, A., Nosova, P., Nikulin, V., Sharova, M., Ignatova, E., Mileyko, V., & Ivanov, M. V. (2023) · Tumori Journal · doi:10.1177/03008916231204441 · Cited by 8
Wang, Q., Tang, Z., Li, C., Li, X., & Su, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1297588 · Cited by 12
Sun, T., Zhao, Q., Zhang, C., Cao, L., Song, M., Maimela, N. R., Liu, S., Wang, J., Gao, Q., Qin, G., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2190 · Cited by 10
Self-citationThe evolving use of pembrolizumab in combination treatment approaches for non-small cell lung cancer
Alexander, M., Ko, B., Lambert, R., Gadgeel, S. M., & Halmos, B. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2020.1702526 · Cited by 9
Vernieri, C., Ganzinelli, M., Rulli, E., Farina, G., Bettini, A., Bareggi, C., Rosso, L., Signorelli, D., Galli, G., Russo, G. L., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000748 · Cited by 8
Immunotherapy Combinations for the Treatment of Patients with Solid Tumors
Bluthgen, M. V., Basté, N., & Recondo, G. (2020) · Future Oncology · doi:10.2217/fon-2020-0303 · Cited by 8
Hita-Millan, J., Carracedo, Á., & Fernández–Rozadilla, C. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11100971 · Cited by 10
Recent advances in lung cancer genomics: Application in targeted therapy
Pathak, N., Chitikela, S. D., & Malik, P. S. (2021) · Advances in genetics · doi:10.1016/bs.adgen.2021.08.004 · Cited by 10
Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
Kulshrestha, R., Kumar, P., Singh, A., Nupur, K., Spalgias, S., Mrigpuri, P., & Rajkumar (2021) · Molecular Biomedicine · doi:10.1186/s43556-021-00061-0 · Cited by 8
Claerhout, S., Lehnert, S., Borght, S. V., Spans, L., Dooms, C., Wauters, E., Vansteenkiste, J., Weynand, B., Deraedt, K., Bourgain, C., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.02.013 · Cited by 8
A STING operation to expose KRAS and STK11 co-mutated lung cancers
Skoulidis, F., Heymach, J. V., & Cascone, T. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.09.010 · Cited by 8
Self-citationYuan, G., Hu, B., Ma, J., Zhang, C., Xie, H., Wei, T., Yang, Y., & Ni, B. (2022) · Cancer Medicine · doi:10.1002/cam4.5451 · Cited by 10
Avelumab in non-small-cell lung cancer
Rosell, R., & Karachaliou, N. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30683-1 · Cited by 8
Ricciuti, B., Brambilla, M., Cortellini, A., Giglio, A. D., Ficorella, C., Sidoni, A., Bellezza, G., Crinò, L., Ludovini, V., Baglivo, S., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02175-y · Cited by 8
What Is the Standard First-Line Treatment for Advanced Non–Small Cell Lung Cancer?
Ricciuti, B., & Awad, M. M. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000489 · Cited by 10
Self-citationLi, Y., Chen, Z., Tao, W., Sun, N., & He, J. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02868-w · Cited by 9
Hyperprogressive disease with immunotherapy: new directions
Lau, S. C. M., & Leighl, N. B. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.88 · Cited by 8
“Due to the widespread use of extended molecular profiling, astute investigators have observed that a subgroup of STK11 and KEAP1 mutant lung cancers derive little benefit from PD-1 inhibition (13,14).”
BackgroundDirect KRAS inhibition: progress, challenges, and a glimpse into the future
Grapsa, D., & Syrigos, K. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1760093 · Cited by 11
“2020, VOL. 20, NO. 6, 437–440 https://doi.org/10.1080/14737140.2020.1760093 © 2020 Informa UK Limited, trading as Taylor & Francis Group inhibition (ICI), even in PD-L1 positive KRAS-mutant NSCLC [18].”
BackgroundInfluentialZhao, J., Wang, L., Zhou, A., Wen, S., Fang, W., Zhang, L., Duan, J., Bai, H., Zhong, J., Wan, R., et al. (2024) · Med · doi:10.1016/j.medj.2024.04.011 · Cited by 10
Self-citationMechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
Gomatou, G., Charpidou, A. G., Li, P., Syrigos, N. K., & Gkiozos, I. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03731-x · Cited by 10
“Several studies have reported that STK11 mutations confer primary resistance to ICIs, with response rates as low as 0–7.4% [40].”
InfluentialBaldi, S., Alnaggar, M., AL-Mogahed, M., Khalil, K., & Zhan, X. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00403-w · Cited by 8
Wang, Y., Li, C., Zhang, T., Wang, J., Liu, W., Deng, L., Jiang, Y., Duan, J., Wang, L., Ge, H., et al. (2025) · View · doi:10.1002/viw.20240145 · Cited by 11
Self-citationShi, X., Deng, W., Pan, Y., Chen, Y., Wang, Y., & Wu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1691980 · Cited by 10
“A phase III-controlled trial (NCT01673867) identi fi ed STK11 / KEAP1 mutations as the most prevalent genomic drivers of primary resistance to a PD-1/L1 therapy in KRAS -mutant lung adenocarcinoma (79).”
Gariazzo, E., Colamartini, F., Ubaldi, M., Santo, V., Brunetti, L., Tomarelli, C., Ognissanti, D., Nassar, J., Costabile, S., Romano, L., et al. (2026) · ImmunoTargets and Therapy · doi:10.2147/itt.s567238 · Cited by 8
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Köhler, J., & Janne, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063025 · Cited by 7
“Finally, approximately 30% of KRAS-mutant tumors harbor subclass-defining co-mutations in TP53, STK11/LKB1 (the latter resulting in loss of LKB1 function) and other genes with emerging clinical and therapeutic relevance [39–43] (summarized in Table 1).”
BackgroundInfluentialDeboever, N., McGrail, D. J., Lee, Y., Tran, H. T., Mitchell, K. G., Antonoff, M. B., Hofstetter, W. L., Mehran, R. J., Rice, D. C., Roth, J. A., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.01.001 · Cited by 9
Self-citationMethods to assess small molecule allosteric modulators of the STRAD pseudokinase
Qing, T., Liu, J., Liu, F., Mitchell, D. C., Beresis, R. T., & Gordan, J. D. (2022) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.03.041 · Cited by 10
Sumii, M., Namba, M., Tokumo, K., Yamauchi, M., Okamoto, W., Hattori, N., & Sugiyama, K. (2023) · Internal Medicine · doi:10.2169/internalmedicine.1110-22 · Cited by 7
“Skoulidis and Arbour report that patients with KRAS mutation-positive lung cancer have STK11 or KEAP1 mutations frequently and have a significantly shorter OS than those without these mutations (2, 3).”
BackgroundImmune landscape and prognostic immune-related signature in KRAS-mutated lung adenocarcinoma
Peng, X., Xia, Z., Guo, Y. S., & Li, Y. (2023) · Aging · doi:10.18632/aging.204770 · Cited by 9
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
“However, co ‐ mutations of other genes, especially STK11/LKB1 and KEAP1 , were found to mediate resistance to anti ‐ PD ‐ 1/PD ‐ L1 therapy in KRAS ‐ mutant NSCLC [159].”
Metadata
- Authors
- Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., Ali, S. M., Elvin, J. A., Singal, G., Ross, J. S., Fabrizio, D., Szabo, P. M., Chang, H., Sasson, A., Srinivasan, S., Kirov, S., Szustakowski, J., Vitazka, P., Edwards, R., Bufill, J. A., Sharma, N., Ou, S.-H. I., Peled, N., Spigel, D. R., Rizvi, H., Aguilar, E. J., Carter, B. W., Erasmus, J., Halpenny, D. F., Plodkowski, A. J., Long, N. M., Nishino, M., Denning, W. L., Galan-Cobo, A., Hamdi, H., Hirz, T., Tong, P., Wang, J., Rodriguez-Canales, J., Villalobos, P. A., Parra, E. R., Kalhor, N., Sholl, L. M., Sauter, J. L., Jungbluth, A. A., Mino-Kenudson, M., Azimi, R., Elamin, Y. Y., Zhang, J., Leonardi, G. C., Jiang, F., Wong, K.-K., Lee, J. J., Papadimitrakopoulou, V. A., Wistuba, I. I., Miller, V. A., Frampton, G. M., Wolchok, J. D., Shaw, A. T., Jänne, P. A., Stephens, P. J., Rudin, C. M., Geese, W. J., Albacker, L. A., & Heymach, J. V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Foundation Medicine (United States) (US)
- Bristol-Myers Squibb (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts General Hospital (US)
- 3Bristol-Myers Squibb Co., Princeton, New Jersey.
- 7Michiana Hematology Oncology, Mishawaka, Indiana.
- 8Novartis Institute of Biomedical Research, East Hanover, New Jersey.
- University of California, Irvine (US)
- Tel Aviv University (IL)
- Sarah Cannon (US)
- 5Lowe Center for Thoracic Oncology and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Brigham and Women's Hospital (US)
- 1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 17Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- NYU Langone Health (US)
- Corresponding author
- Albacker, Lee A.
- Heymach, John V.
- ORCID
- Skoulidis, Ferdinandos
- Goldberg, Michael E.
- Greenawalt, Danielle M.
- Hellmann, Matthew D.
- Awad, Mark M.
- Gainor, Justin F.
- Schrock, Alexa B.
- Hartmaier, Ryan J.
- Trabucco, Sally E.
- Gay, Laurie
- Ali, Siraj M.
- Elvin, Julia A.
- Ross, Jeffrey S.
- Fabrizio, David
- Sasson, Ariella
- Srinivasan, Sujaya
- Kirov, Stefan
- Szustakowski, Joseph
- Edwards, Robin
- Sharma, Neelesh
- Ou, Sai-Hong I.
- Peled, Nir
- Spigel, David R.
- Rizvi, Hira
- Carter, Brett W.
- Plodkowski, Andrew J.
- Nishino, Mizuki
- Denning, Warren L.
- Hirz, Taghreed
- Tong, Pan
- Wang, Jing
- Parra, Edwin R.
- Kalhor, Neda
- Sholl, Lynette M.
- Sauter, Jennifer L.
- Jungbluth, Achim A.
- Mino-Kenudson, Mari
- Elamin, Yasir Y.
- Zhang, Jianjun
- Leonardi, Giulia C.
- Jiang, Fei
- Wong, Kwok-Kin
- Papadimitrakopoulou, Vassiliki A.
- Wistuba, Ignacio I.
- Miller, Vincent A.
- Frampton, Garrett M.
- Wolchok, Jedd D.
- Shaw, Alice T.
- Rudin, Charles M.
- Geese, William J.
- Albacker, Lee A.
- Heymach, John V.
- Venue
- Cancer Discovery
- Published
- 2018-07-01
- Volume
- 8
- Issue
- 7
- Pages
- 822-835
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC6030433
- OpenAlex
- W2804812017
- Cited by
- 1,641
- References
- 56
- Citations by year
- 2026: 182 · 2025: 191 · 2024: 196 · 2023: 211 · 2022: 223 · 2021: 264 · 2020: 239 · 2019: 108 · 2018: 26
- FWCI
- 59.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Association for Cancer Research (AACR) (SU2C-AACR-DT17-15)
- HHS | NIH | National Cancer Institute (NCI) (P30 CA016672, P30 CA008748, P50 CA070907, 1R01 CA205150, 1R01 CA203636)
- Sabin Family Foundation (Sabin Family Foundation Fellowship)
- Khalifa Bin Zayed Al Nahyan Foundation (Khalifa Bin Zayed Al Nahyan Foundation Scholar Award)
- Jane Ford-Petrin Fund (Jane Ford-Petrin Fund)
- Cancer Prevention and Research Institute of Texas (CPRIT) (RP160652)
- V Foundation for Cancer Research (V Foundation) (V Foundation Translational Award)
- The University of Texas MD Anderson Lung Cancer Moonshots Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- KRAS-mutant lung adenocarcinoma, anti-PD-1 resistance, PD-L1 expression, tumor mutational burden, nivolumab, immune checkpoint inhibitors, TP53 mutation, non-small cell lung cancer, immunotherapy biomarkers, combination immunotherapy, progression-free survival
- MeSH terms
- Antineoplastic Agents, Immunological, Adenocarcinoma of Lung, Nivolumab, Progression-Free Survival, AMP-Activated Protein Kinase Kinases, Adult, Aged, Aged, 80 and over, Animals, Disease Models, Animal, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Mutation, Prognosis, Proto-Oncogene Proteins p21(ras), Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.